Detalhe da pesquisa
1.
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Diabetes Obes Metab;
25(3): 832-843, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36478142
2.
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
Eur Heart J;
42(6): 700-710, 2021 02 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33351892
3.
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
N Engl J Med;
376(17): 1627-1636, 2017 04 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28317415
4.
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
N Engl J Med;
377(16): 1513-1524, 2017 10 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28844193
5.
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Eur Heart J;
40(19): 1553-1562, 2019 05 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30793734
6.
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled.
Circulation;
147(1): 101-104, 2023 01 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36342827
7.
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Am Heart J;
212: 13-22, 2019 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30928824
8.
Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled.
Arterioscler Thromb Vasc Biol;
43(7): 1334-1337, 2023 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37199158
9.
Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study.
Europace;
21(6): 879-885, 2019 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30982849
10.
Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
Diabetes Obes Metab;
19(2): 266-274, 2017 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27762093
11.
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
N Engl J Med;
377(5): 495-6, 2017 08 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28767343
12.
Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.
J Cachexia Sarcopenia Muscle;
15(1): 412-424, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38158636
13.
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced.
JACC Heart Fail;
12(1): 35-46, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37715769
14.
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.
Eur J Heart Fail;
25(10): 1797-1805, 2023 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37540060
15.
[Pharmacoepidemiological study of the use of psychotropics in hospitalized patients]. / Estudio farmacoepidemiológico de la utilización de psicofármacos en pacientes internados.
Vertex;
23(102): 98-103, 2012.
Artigo
em Espanhol
| MEDLINE
| ID: mdl-23139919
16.
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.
Eur Heart J Cardiovasc Pharmacother;
8(3): 216-226, 2022 05 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33258897
17.
Cardiovascular disease in the elderly: proceedings of the European Society of Cardiology-Cardiovascular Round Table.
Eur J Prev Cardiol;
29(10): 1412-1424, 2022 08 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35167666
18.
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Lancet Diabetes Endocrinol;
10(1): 35-45, 2022 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34861154
19.
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials).
Clin Cardiol;
44(7): 1002-1010, 2021 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34042199
20.
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial.
JACC Cardiovasc Interv;
14(7): 768-780, 2021 04 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33826497